US EPA

527690 

Journal Article 

Review 

Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction 

Thadani, U; Ripley, TL 

2007 

Yes 

Expert Opinion on Drug Safety
ISSN: 1474-0338 

6 

4 

385-396 

English 

17688382 

10.1517/14740338.6.4.385 

WOS:000248391600005 

Nitrates are potent venous dilators and anti-ischemic agents. They are widely used for the relief of chest pain and pulmonary congestion in patients with acute coronary syndromes and heart failure. Nitrates, however, do not reduce mortality in patients with acute coronary syndromes. Combination of nitrates and hydralazine when given in addition to beta-blockers and angiotensin-converting enzyme (ACE) inhibitors reduce mortality and heart failure hospitalizations in patients with heart failure due to left ventricular systolic dysfunction who are of African-American origin. Side effects during nitrate therapy are common but are less well described in the literature compared with the reported side effects in patients with stable angina pectoris. The reported incidence of side effects varies highly among different studies and among various disease states. Headache is the most commonly reported side effect with an incidence of 12% in acute heart failure, 41 - 73% in chronic heart failure, 3 - 19% in unstable angina and 2 - 26% in acute myocardial infarction. The reported incidence of hypotension also differs: 5-10% in acute heart failure, 20% in chronic heart failure, 3 - 19% in unstable angina and < 1 - 48% in acute myocardial infarction, with the incidence being much higher with concomitant nitrate therapy plus angiotensin-converting enzyme inhibitors. Reported incidence of dizziness is as low as 1 % in patients with acute myocardial infarction to as high as 29% in patients with heart failure. Severe headaches and/or symptomatic hypotension may necessitate discontinuation of nitrate therapy. Severe life threatening hypotension or even death may occur when nitrates are used in patients with acute inferior myocardial infarction associated with right ventricular dysfunction or infarction, or with concomitant use of phosphodiesterase-5 inhibitors or N-acetylcysteine. Despite the disturbing observational reports in the literature that continuous and prolonged use of nitrates may lead to increased mortality and recurrent myocardial infarction in patients with stable coronary artery disease, no such adverse effects of nitrates have been reported in the large randomized trials in patients with acute myocardial infarction or chronic heart failure. 

acute coronary syndromes; adverse effects; heart failure; isosorbide-dinitrate; isosorbide-5-mononitrate; myocardial infarction; nitroglycerin; organic nitrates; unstable angina; right ventricular infarction; increases cardiac events; intravenous; nitroglycerin; isosorbide dinitrate; stable angina; long-term; transdermal nitroglycerin; n-acetylcysteine; double-blind; randomized-trial